P2Y12 Inhibitors and Mortality in Patients Hospitalized With Intracerebral Hemorrhage - Takeaways - MDSpire

P2Y12 Inhibitors and Mortality in Patients Hospitalized With Intracerebral Hemorrhage

  • By

  • Chen Jin

  • Ying Song

  • Brian Mac Grory

  • Jie-Lena Sun

  • Brooke Alhanti

  • Gregg C. Fonarow

  • Lee H. Schwamm

  • Kevin N. Sheth

  • Eric E. Smith

  • Steven R. Messé

  • Jeffrey L. Saver

  • Deepak L. Bhatt

  • Ying Xian

  • July 9, 2026

  • 0 min

Share

  • 1

    P2Y12 inhibitors are critical in managing coronary artery and cerebrovascular diseases but pose a risk of intracerebral hemorrhage (ICH).

  • 2

    The study utilized the AHA/ASA GWTG-Stroke registry to analyze clinical outcomes of patients with ICH receiving different antiplatelet therapies.

  • 3

    Primary outcomes included stroke severity measured by NIHSS and in-hospital mortality, with severe stroke defined as an NIHSS score of 21 or higher.

  • 4

    Secondary outcomes assessed functional independence at discharge using the modified Rankin Scale (mRS), with scores ranging from 0 to 6.

  • 5

    The study aimed to compare outcomes among patients on P2Y12 inhibitor monotherapy, dual antiplatelet therapy, aspirin monotherapy, or no therapy.

Original Source(s)

P2Y12 Inhibitors and Mortality in Patients Hospitalized With Intracerebral Hemorrhage

  • by Chen Jin, Ying Song, Brian Mac Grory, Jie-Lena Sun, Brooke Alhanti, Gregg C. Fonarow, Lee H. Schwamm, Kevin N. Sheth, Eric E. Smith, Steven R. Messé, Jeffrey L. Saver, Deepak L. Bhatt, Ying Xian

  • July 9, 2026

Related Content

Prediction model for early neurological deterioration in large artery atherosclerotic stroke

Editorial: AI-driven smart sensing and processing for personalized healthcare

Top 10 Evidence-Based Essentials in Neurology

A structured framework of guidelines, trials, therapies, and tools used in clinical practice.